An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells

Blood

Volumn 117, Issue 16, 2011, Pages 4262-4272

  Sergeeva, Anna ^a   Alatrash, Gheath ^a   He, Hong ^a   Ruisaard, Kathryn ^a   Lu, Sijie ^a   Wygant, James ^a,b   McIntyre, Bradley W ^a   Ma, Qing ^a   Li, Dan ^a   St John, Lisa ^a   Clise Dwyer, Karen ^a   Molldrem, Jeffrey J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Bio Scientific Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; HLA A2 ANTIGEN; IMMUNOGLOBULIN G2A ANTIBODY; PR1 ANTIGEN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANIMAL EXPERIMENT; ANTIBODY SCREENING; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; CELL ADHESION; CELL GROWTH; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOGENETICS; CYTOLYSIS; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYBRIDOMA; IMMUNIZATION; INJECTION; LEUKOCYTE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL; TARGET CELL DESTRUCTION;

EID: 79955966609     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-299248     Document Type: Article

References (50)

1. Tamaki H, Ogawa H, Inoue K, et al. Increased expression of the Wilms tumor gene (WT1) at relapse in acute leukemia. Blood. 1996;88(11): 4396-4398. (Pubitemid 26399190)
2. Rosenfeld C, Cheever MA, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia. 2003;17(7):1301-1312. (Pubitemid 36857337)
3. Scheibenbogen C, Letsch A, Thiel E, et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood. 2002;100(6):2132-2137. (Pubitemid 35001248)
4. Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6(9):1018-1023.
5. Kanodia S, Wieder E, Lu S, et al. PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal. PLoS ONE. 2010; 5(7):e11770.
6. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A. 2004;101(38): 13885-13890. (Pubitemid 39298502)
7. Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008;111(1):236-242.
8. Krogsgaard M, Wucherpfennig KW, Cannella B, et al. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2- MBP 85-99 complex. J Exp Med. 2000;191(8): 1395-1412. (Pubitemid 30227126)
9. Chames P, Hufton SE, Coulie PG, Uchanska- Ziegler B, Hoogenboom HR. Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library. Proc Natl Acad Sci U S A. 2000;97(14):7969-7974. (Pubitemid 30460757)
10. Bernardeau K, Gouard S, David G, et al. Assessment of CD8 involvement in T cell clone avidity by direct measurement of HLA-A2/Mage3 complex density using a high-affinity TCR like monoclonal antibody. Eur J Immunol. 2005;35(10):2864-2875. (Pubitemid 41555082)
11. Wittman VP,Woodburn D, Nguyen T, Neethling FA, Wright S,Weidanz JA. Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death. J Immunol. 2006;177(6):4187-4195. (Pubitemid 44359954)
12. Andersen PS, Stryhn A, Hansen BE, Fugger L, Engberg J, Buus S. A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Proc Natl Acad Sci U S A. 1996;93(5):1820-1824. (Pubitemid 26079838)
13. Held G, Matsuo M, Epel M, et al. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. Eur J Immunol. 2004;34(10):2919-2929. (Pubitemid 39430167)
14. Epel M, Carmi I, Soueid-Baumgarten S, et al. Targeting TARP, a novel breast and prostate tumorassociated antigen, with T cell receptor-like human recombinant antibodies. Eur J Immunol. 2008;38(6):1706-1720.
15. Klechevsky E, Gallegos M, Denkberg G, et al. Antitumor activity of immunotoxins with T-cell receptor- like specificity against human melanoma xenografts. Cancer Res. 2008;68(15):6360-6367.
16. Verma B, Neethling FA, Caseltine S, et al. TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models. J Immunol. 184(4):2156-2165.
17. Molldrem JJ, Clave E, Jiang YZ, et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood. 1997; 90(7):2529-2534. (Pubitemid 27413460)
18. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367(6464): 645-648. (Pubitemid 24067706)
19. Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 1999;59(11):2675-2681. (Pubitemid 29269115)
20. Weidanz JA, Piazza P, Hickman-Miller H, et al. Development and implementation of a direct detection, quantitation and validation system for class I MHC self-peptide epitopes. J Immunol Methods. 2007;318(1-2):47-58. (Pubitemid 46026805)
21. Altman JD, Davis MM. MHC-peptide tetramers to visualize antigen-specific T cells. Curr Protoc Immunol. 2003;Chapter 17:Unit 17.3.
22. Prang N, Preithner S, Brischwein K, et al. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br J Cancer. 2005;92(2):342-349. (Pubitemid 40343151)
23. Molldrem J, Dermime S, Parker K, et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood. 1996;88(7):2450-2457. (Pubitemid 26327493)
24. Hanley PJ, Cruz CR, Savoldo B, et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009;114:1958-1967.
25. Bednarek MA, Sauma SY, Gammon MC, et al. The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2. J Immunol. 1991;147(12):4047-4053.
26. van der Harst D, Goulmy E, Falkenburg JH, et al. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood. 1994;83(4):1060-1066. (Pubitemid 24058556)
27. Stewart-Jones G, Wadle A, Hombach A, et al. Rational development of high-affinity T-cell receptor-like antibodies. Proc Natl Acad Sci U S A. 2009;106(14):5784-5788.
28. Hogan KT, Brown SL. Localization and characterization of serologic epitopes on HLA-A2. Hum Immunol. 1992;33(3):185-192.
29. McMichael AJ, Parham P, Rust N, Brodsky F. A monoclonal antibody that recognizes an antigenic determinant shared by HLAA2 and B17. Hum Immunol. 1980;1(2):121-129. (Pubitemid 12238821)
30. Santos-Aguado J, Barbosa JA, Biro PA, Strominger JL. Molecular characterization of serologic recognition sites in the human HLA-A2 molecule. J Immunol. 1988;141(8):2811-2818. (Pubitemid 18263073)
31. Teng JM, Hogan KT. Both major and minor peptide- binding pockets in HLA-A2 influence the presentation of influenza virus matrix peptide to cytotoxic T lymphocytes. Mol Immunol. 1994;31(6): 459-470. (Pubitemid 24153330)
32. Teng JM, Hogan KT. Residues outside of the HLA-A2 peptide-binding groove can abrogate or enhance recognition of influenza virus matrix peptide pulsed cells by cytotoxic T lymphocytes. Mol Immunol. 1994;31(6):445-457. (Pubitemid 24153329)
33. Molldrem JJ, Lee PP, Kant S, et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest. 2003;111(5):639-647. (Pubitemid 36278582)
34. Zimmer M, Medcalf RL, Fink TM, Mattmann C, Lichter P, Jenne DE. Three human elastase-like genes coordinately expressed in the myelomonocyte lineage are organized as a single genetic locus on 19pter. Proc Natl Acad Sci U S A. 1992; 89(17):8215-8219.
35. Muller-Bérat N, Minowada J, Tsuji-Takayama K, et al. The phylogeny of proteinase 3/myeloblastin, the autoantigen in Wegener's granulomatosis, and myeloperoxidase as shown by immunohistochemical studies on human leukemic cell lines. Clin Immunol Immunopathol. 1994;70(1):51-59. (Pubitemid 24034689)
36. Egesten A, Breton-Gorius J, Guichard J, Gullberg U, Olsson I. The heterogeneity of azurophil granules in neutrophil promyelocytes: immunogold localization of myeloperoxidase, cathepsin G, elastase, proteinase 3, and bactericidal/permeability increasing protein. Blood. 1994;83(10):2985-2994. (Pubitemid 24142733)
37. Sturrock A, Franklin KF, Hoidal JR. Human proteinase-3 expression is regulated by PU.1 in conjunction with a cytidine-rich element. J Biol Chem. 1996;271(50):32392-32402. (Pubitemid 26422282)
38. Woolhiser MR, Brockow K, Metcalfe DD. Activation of human mast cells by aggregated IgG through FcgammaRI: additive effects of C3a. Clin Immunol. 2004;110(2):172-180. (Pubitemid 38296707)
39. Beum PV, Kennedy AD, Taylor RP. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. J Immunol Methods. 2004;289(1-2):97-109. (Pubitemid 38900908)
40. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non- Hodgkin's lymphoma. Ann Oncol. 1998;9(9):995-1001. (Pubitemid 28496709)
41. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004;5(7):738-743. (Pubitemid 39023306)
42. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105-111. (Pubitemid 33041634)
43. Vogel CW, Muller-Eberhard HJ. Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase. Proc Natl Acad Sci U S A. 1981;78(12):7707-7711. (Pubitemid 12186631)
44. Weiner GJ. Monoclonal antibody mechanisms of action in cancer. Immunol Res. 2007;39(1-3):271-278. (Pubitemid 47574893)
45. Durrant LG, Harding SJ, Green NH, Buckberry LD, Parsons T. A new anticancer glycolipid monoclonal antibody, SC104, which directly induces tumor cell apoptosis. Cancer Res. 2006;66(11): 5901-5909. (Pubitemid 43927145)
46. Kaiafa G, Papadopoulos A, Ntaios G, et al. Detection of CD55- and CD59-deficient granulocytic populations in patients with myelodysplastic syndrome. Ann Hematol. 2008;87(4):257-262.
47. Guc D, Canpinar H, Kucukaksu C, Kansu E. Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies. Eur J Haematol. 2000;64(1):3-9. (Pubitemid 30055538)
48. Hatanaka M, Seya T, Matsumoto M, et al. Mechanisms by which the surface expression of the glycosyl-phosphatidylinositol-anchored complement regulatory proteins decay-accelerating factor (CD55) and CD59 is lost in human leukaemia cell lines. Biochem J. 1996;314(pt 3):969-976.
49. Jacobs H. TCR-independent T cell development mediated by gain-of-oncogene function or loss-of-tumor-suppressor gene function. Semin Immunol. 2000;12(5):487-502.
50. van der Merwe PA, Davis SJ. Molecular interactions mediating T cell antigen recognition. Annu Rev Immunol. 2003;21:659-684. (Pubitemid 37174544)